Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast
Rhea-AI Summary
Co-Diagnostics (NASDAQ: CODX), a molecular diagnostics company known for its patented diagnostic test development platform, has scheduled its first quarter 2025 earnings release for Thursday, May 8, 2025, after market close.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Key executives participating include:
- Dwight Egan - Chief Executive Officer
- Brian Brown - Chief Financial Officer
- Andrew Benson - Head of Investor Relations
Investors and analysts can access the event through:
- Webcast: Available on ir.codiagnostics.com (Events & Webcasts page)
- Conference Call: Toll-free (800-715-9871) or Toll (646-307-1963)
- Passcode: 1977478
A recording will be available on the company's website for those unable to attend the live session.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CODX declined 3.48%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
The conference call and webcast will be available via:
Webcast: ir.codiagnostics.com on the Events & Webcasts page, or accessible directly here
Conference Call: 800-715-9871 (Toll Free) or (646) 307-1963 (Toll) with participant passcode 1977478
If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.
Investor Relations Contact:
Andrew Benson
Head of Investor Relations
+1 801-438-1036
investors@codiagnostics.com
FAQ
When will Co-Diagnostics (CODX) release Q1 2025 earnings?
How can investors join Co-Diagnostics Q1 2025 earnings call?
What time is CODX earnings call on May 8, 2025?
Can I listen to CODX Q1 2025 earnings call recording later?
Which executives will present at Co-Diagnostics Q1 2025 earnings call?
